Published in Cell Cycle on February 11, 2008
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood (2010) 2.84
Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development. PLoS One (2009) 1.29
Bax, Bcl2, and p53 differentially regulate neomycin- and gentamicin-induced hair cell death in the zebrafish lateral line. J Assoc Res Otolaryngol (2013) 1.05
Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos. Mol Cancer Ther (2009) 0.93
RCAD/Ufl1, a Ufm1 E3 ligase, is essential for hematopoietic stem cell function and murine hematopoiesis. Cell Death Differ (2015) 0.92
Differential regulation of p53 function by the N-terminal ΔNp53 and Δ113p53 isoforms in zebrafish embryos. BMC Dev Biol (2010) 0.91
Evaluation of the fullerene compound DF-1 as a radiation protector. Radiat Oncol (2010) 0.84
HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4(+) T cells. Oncogene (2016) 0.77
Phenotype anchoring in zebrafish reveals a potential role for matrix metalloproteinases (MMPs) in tamoxifen's effects on skin epithelium. Toxicol Appl Pharmacol (2016) 0.76
Graft-versus-host disease-related cytokine-driven apoptosis depends on p73 in cytokeratin 15-positive target cells. Biol Blood Marrow Transplant (2012) 0.75
Pro-apoptotic Effect of Pifithrin-α on Preimplantation Porcine In vitro Fertilized Embryo Development. Asian-Australas J Anim Sci (2012) 0.75
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst (2013) 2.35
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys (2012) 2.12
The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys (2012) 2.10
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer (2011) 1.76
Differentiation and definition of vascular-targeted therapies. Clin Cancer Res (2005) 1.74
Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell (2002) 1.71
Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer (2011) 1.70
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther (2002) 1.57
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer (2003) 1.56
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (2011) 1.55
Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther (2004) 1.55
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. Int J Radiat Oncol Biol Phys (2012) 1.54
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology (2009) 1.45
Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT. Urology (2009) 1.43
Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Sci (2007) 1.39
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Patient-oriented cancer information on the internet: a comparison of wikipedia and a professionally maintained database. J Oncol Pract (2011) 1.31
Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res (2003) 1.29
Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development. PLoS One (2009) 1.29
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res (2010) 1.22
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys (2008) 1.22
Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist (2013) 1.20
Biochemical and structural characterization of the Pak1-LC8 interaction. J Biol Chem (2008) 1.17
Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol (2010) 1.16
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res (2004) 1.13
Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int J Radiat Oncol Biol Phys (2005) 1.11
Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc Natl Acad Sci U S A (2011) 1.09
Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene (2002) 1.08
Specific sequences in p120ctn determine subcellular distribution of its multiple isoforms involved in cellular adhesion of normal and malignant epithelial cells. J Cell Sci (2002) 1.07
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther (2008) 1.06
Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev (2012) 1.06
Selectively starving cancer cells through dietary manipulation: methods and clinical implications. Future Oncol (2013) 1.05
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys (2007) 1.04
E-cadherin loss promotes the initiation of squamous cell carcinoma invasion through modulation of integrin-mediated adhesion. J Cell Sci (2006) 1.03
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys (2012) 1.02
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin Cancer Res (2006) 1.02
The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. Int J Gynecol Cancer (2012) 1.01
Cells expressing partially unfolded R789C/p.R989C type II procollagen mutant associated with spondyloepiphyseal dysplasia undergo apoptosis. Hum Mutat (2008) 1.00
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res (2009) 0.99
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res (2006) 0.98
Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxyprolyl-phosphono peptide nucleic acids. Nucleic Acids Res (2005) 0.97
Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys (2011) 0.96
Cell autonomous expression of inflammatory genes in biologically aged fibroblasts associated with elevated NF-kappaB activity. Immun Ageing (2008) 0.96
Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys (2003) 0.94
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst (2012) 0.94
Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos. Mol Cancer Ther (2009) 0.93
Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States. Int J Radiat Oncol Biol Phys (2012) 0.93
EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities. Cancer Biol Ther (2006) 0.93
On the merits and limitations of whole-brain radiation therapy. J Clin Oncol (2012) 0.93
Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev (2013) 0.92
Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base. Brachytherapy (2005) 0.91
Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. BMC Genomics (2012) 0.91
Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results. Ultrasound Med Biol (2002) 0.91
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys (2006) 0.91
Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis. Am J Clin Oncol (2013) 0.91
Differential regulation of p53 function by the N-terminal ΔNp53 and Δ113p53 isoforms in zebrafish embryos. BMC Dev Biol (2010) 0.91
Reliability of EUCLIDIAN: an autonomous robotic system for image-guided prostate brachytherapy. Med Phys (2011) 0.90
Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol (2013) 0.90
Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol (2012) 0.89
Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer (2013) 0.89
Reanalysis of cancer drugs: old drugs, new tricks. Clin Cancer Res (2004) 0.89
Implanted dosimeters identify radiation overdoses during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.89
Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation. Front Oncol (2013) 0.89
Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol (2015) 0.89
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer (2012) 0.89
Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys (2009) 0.89
Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: can implant quality be predicted on day 0? Int J Radiat Oncol Biol Phys (2002) 0.87
Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther (2005) 0.87
Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol (2002) 0.87
Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am (2004) 0.87
Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol (2010) 0.86